Pharmaceutical Executive, July 2022 Issue (PDF)

Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive-07-01-2022
Volume 42
Issue 7

Click cover to access PDF

Download Issue PDF
Articles in this issue
The True Nature of Danger Behind IP Waiver Proposal
The True Nature of Danger Behind IP Waiver Proposal
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent Contractors
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent Contractors
Cracking Down on Speaker Programs
Cracking Down on Speaker Programs
Dynamic Compliance: The Best Defense for Pharma
Dynamic Compliance: The Best Defense for Pharma
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
Breaking Down Barriers
Breaking Down Barriers
Biotech Performance Glance—and Promising Ripples for Recovery
Biotech Performance Glance—and Promising Ripples for Recovery
If Non-Formulary Hospital, Price May Not Be the Rx
If Non-Formulary Hospital, Price May Not Be the Rx
When It Comes To DE&I, Silence Is Deafening
When It Comes To DE&I, Silence Is Deafening
Asia’s Rise in The Global Pharma Industry
Asia’s Rise in The Global Pharma Industry
Rewriting European Regulations on Rare Disease Treatments
Rewriting European Regulations on Rare Disease Treatments
High-Value Views, Input
High-Value Views, Input
Pharmaceutical Executive, July 2022 Issue (PDF)
Pharmaceutical Executive, July 2022 Issue (PDF)
Orphan Drugs: From Niche to Mainstream
Orphan Drugs: From Niche to Mainstream
FDA Advances Quality Initiatives to Combat Drug Shortages
FDA Advances Quality Initiatives to Combat Drug Shortages
Recent Videos
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
Satish Shenoy

Generative AI and Digital Workers: Accelerating Innovation in the Pharma Industry

Satish Shenoy
March 31st 2025
Article

If used properly, AI can be a game-changer for drug development.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

FDA Approves AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer

FDA Approves AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer

Don Tracy, Associate Editor
March 31st 2025
Article

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Pharma Pulse 3/31/25: The Impact of Funding Cuts on Medical Research, Training Pharmacy Technicians as Community Health Workers & more

Pharma Pulse 3/31/25: The Impact of Funding Cuts on Medical Research, Training Pharmacy Technicians as Community Health Workers & more

Miranda Schmalfuhs
March 31st 2025
Article

The latest news for pharma industry insiders.

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Don Tracy, Associate Editor
March 31st 2025
Article

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.